Dashboard
Financial statements
CRL

Company financials

Charles River Laboratories

Health Care Life Sciences Tools & Services Wilmington, Massachusetts Last filing Feb 18, 2026 · FY2025
Revenue FY2025
$4.0B
3y CAGR +0.3% P15
Net income FY2025
$-144.3M
Net margin -3.6% P8
Total assets FY2025
$7.1B
ROA -2.0% P8
Operating cash flow FY2025
$737.6M
18 yrs · FY2008–FY2025 9 filed · 0 derived · 0 blank

Year-over-year change per cell; first column has no prior.

Balance Sheet

Assets, liabilities, and equity

33 accounts · 10 years
Total assets $7.1B
Total liabilities $3.9B
Shareholders equity $3.2B
Account 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 Trend
Assets
Cash and Cash Equivalents +9.8% -29.7% +18.3% -3.0% +5.6% -4.0% +21.8% +19.3% +39.2%
Accounts Receivable -1.7% -7.6% +3.7% +17.0% +4.1% +20.2% +8.8% +9.8% +18.1%
Inventory
Prepaid Expenses
Total Current Assets +3.1% -12.8% +11.8% +12.9% +6.1% +17.6% +13.8% +8.6% +25.9%
Property,Plant and Equipment +3.2% -2.2% +11.9% +13.5% +14.8% +7.7% -61.1% +242.9% +3.5%
Operating Lease Assets -12.4% +4.7% +0.6% +33.7% +64.4% +27.2%
Goodwill -2.9% -8.0% +8.6% +5.1% +49.9% +17.4% +23.5% +54.9% +2.2%
Intangible Assets
Long Term Investments
Deferred Tax Assets -78.8% +9.4% +603.6% -81.3% +30.6% +10.9% +88.7% -0.7% -38.9%
Other Noncurrent Assets +5.4% -10.1% +108.6% -2.1% -57.0% +65.9% +892.7% -82.7% +40.2%
Total Assets -5.2% -8.1% +7.8% +8.2% +27.9% +17.0% +21.7% +31.6% +8.0%
Liabilities
Accounts Payable +6.0% -16.9% -18.0% +3.9% +61.8% +9.8% +68.3% -14.9% +13.7%
Accrued Liabilities +16.4% +1.8% +3.7% -4.0% +52.7% +7.7% +30.1% +19.1% +6.3%
Deferred Revenue
Current Portion of Long Term Debt
Operating Lease Liabilities
Other Current Liabilities +14.5% -4.5% -0.7% +45.7% +37.0% +13.1% +2887.1% -93.2% +67.8%
Total Current Liabilities +12.7% -5.8% -3.3% +5.7% +23.0% +18.2% +27.2% +20.4% +7.9%
Operating Lease Liabilities Noncurrent -10.3% +15.4% +7.6% +54.1% +62.6% +33.8%
Deferred Tax Liabilities
Other Noncurrent Liabilities -29.2% -12.5% +27.7% -28.0% +18.3% +12.2% +2.1% -8.1% +22.3%
Total Liabilities -2.4% -11.4% -0.9% +3.3% +32.4% +10.6% +20.2% +34.9% +0.4%
Equity
Preferred Stock
Common Stock -3.7% -0.4% +0.8% +0.8% +1.4% +1.8% +1.5% -44.9% +1.4%
Additional Paid In Capital -1.0% +3.2% +5.6% +5.0% +5.6% +6.3% +5.8% -43.5% +3.3%
Retained Earnings
Treasury Stock -100.0% +393.4% -100.0% +69.8% +32.6% +30.6% -87.0% -93.1%
Accumulated Other Comprehensive Income
Noncontrolling Interest
Total Stockholders Equity -8.6% -3.8% +20.9% +17.4% +19.9% +29.4% +24.1% +26.1% +24.9%
Total Liabilitiesand Equity -4.6% -8.0% +7.0% +9.1% +27.6% +17.2% +21.5% +31.7% +7.3%

Key Ratios

Margins, returns, liquidity, leverage, efficiency

Computed at import · 10 years
Ratio 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
Profitability
Gross margin +83.5%
Operating margin +0.6% +5.6% +14.9% +16.4% +16.7% +14.8% +13.4% +14.6% +15.5% +14.1%
Net margin -3.6% +0.5% +11.5% +12.2% +11.0% +12.5% +9.6% +10.0% +6.6% +9.2%
FCF margin
Growth
Revenue CAGR (3y) +0.3% +4.6% +12.2% +14.9% +16.0% +16.3% +16.0% +18.5% +12.7% +13.0%
Returns
ROE -4.6% +0.6% +13.2% +16.3% +15.4% +17.2% +15.4% +17.2% +11.8% +18.5%
ROA -2.0% +0.3% +5.8% +6.4% +5.6% +6.6% +5.4% +5.9% +4.2% +5.7%
ROIC +0.9% +7.0% +18.6% +18.8% +25.7% +22.4% +24.5% +11.9% +14.4% +8.6%
Liquidity
Current ratio 1.29x 1.41x 1.52x 1.32x 1.23x 1.43x 1.44x 1.61x 1.78x 1.53x
Quick ratio 0.82x 0.92x 1.00x 0.90x 0.86x 1.01x 1.06x 1.20x 1.28x 1.12x
Leverage
D/E 1.24x 1.16x 1.26x 1.54x 1.75x 1.58x 1.85x 1.91x 1.79x 2.22x
Interest coverage 0.24x 4.52x 10.98x 7.98x 5.01x 5.77x 5.20x 9.68x 8.57x
Efficiency
Asset turnover 0.56x 0.54x 0.50x 0.52x 0.50x 0.53x 0.56x 0.59x 0.63x 0.62x
Cash conversion cycle +115d

Valuation

Price against fundamentals

FY2025 fundamentals · no price

No price data cached, so there is nothing to multiply. Load prices from the Stock Data tab and this panel reprices itself.

Notes

Your annotations

Not watched
Saving notes adds CRL to your watchlist.